{"id":55256,"date":"2023-03-28T14:06:47","date_gmt":"2023-03-28T12:06:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/"},"modified":"2023-03-28T14:06:47","modified_gmt":"2023-03-28T12:06:47","slug":"adacore-launches-recordflux","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/","title":{"rendered":"AdaCore Launches RecordFlux"},"content":{"rendered":"
\n

\nInnovative software technology enables developing provable, secure communication protocols<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–#AdaCore<\/a>—AdaCore<\/a>, a trusted provider of software development and verification tools, today announced the launch of its new RecordFlux<\/a> technology, designed to ease the development and security of binary communication protocols. The technology comprises a Domain Specific Language (DSL) to precisely describe complex binary data formats and communication protocols, and a toolset to verify specifications and generate provable SPARK code that can be executed on a target CPU.\n<\/p>\n

\nThrough RecordFlux, users can define and implement complex communication protocols and prove security properties, such as memory safety, at much less cost and effort than would be possible with a manual approach. The precision of the RecordFlux DSL ensures that the specifications are unambiguous, the high-level nature of the DSL makes the specifications easily understandable by domain experts, and the expressive power of the DSL can capture the most complex real-world protocols. And since the RecordFlux code generator produces source code in the formal methods-based SPARK language, users can obtain automated proofs of a wide range of security properties in the resulting software. The net effect is more secure and reliable code, at lower cost.\n<\/p>\n

\n\u201cInteraction between software components is governed by protocol and format specifications. Unfortunately, most specification documents are complex texts written in English which need to be translated to software implementations manually, leaving room for human error,\u201d said Alex Senier, AdaCore\u2019s RecordFlux Team Lead. \u201cLogic errors and critical flaws are often poorly mitigated by the widespread use of unsafe programming languages, resulting in severe security vulnerabilities. With RecordFlux, we aim to provide a solution that saves time and money by automating provable code generation while ensuring the absence of low-level vulnerabilities like buffer overflows that attackers could exploit.\u201d\n<\/p>\n

\nAbout RecordFlux
\n
<\/b>RecordFlux is a toolset for creating high-assurance implementations of binary data formats and communication protocols. The technology includes a Domain Specific Language, a comprehensive toolset, and customized expert support. By using SPARK Pro<\/a>, developers can take the SPARK code generated from RecordFlux specifications and automatically prove that the code is free of run-time errors and respects the original specification.\n<\/p>\n

\nCode generated by RecordFlux is also compatible with GNAT Pro Assurance<\/a>, AdaCore\u2019s complete solution for projects with the most stringent requirements for reliability, long-term maintenance, or certification. The compiler-hardening options provided by GNAT Pro Assurance can be used to mitigate further attacks on network-facing protocol-handling code.\n<\/p>\n

\nFor more information about the RecordFlux technology, please visit www.adacore.com\/recordflux<\/a>.\n<\/p>\n

\nAbout AdaCore
\n
<\/b>Founded in 1994, AdaCore supplies software development and verification tools for mission-critical, safety-critical, and security-critical systems.\n<\/p>\n

\nOver the years, customers have used AdaCore products to field and maintain a wide range of critical applications in domains such as commercial and military avionics, defense systems, automotive, railway, space, air traffic management\/control, medical devices, and financial services. AdaCore has an extensive and growing worldwide customer base; see www.adacore.com\/industries<\/a> for further information.\n<\/p>\n

\nAdaCore products are open source and come with expert online support provided by the developers themselves. The company has North American headquarters in New York and European headquarters in Paris. www.adacore.com<\/a>.\n<\/p>\n

\nhttp:\/\/www.adacore.com<\/a>
http:\/\/twitter.com\/AdaCoreCompany<\/a>
https:\/\/www.linkedin.com\/company\/adacore\/<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPress<\/b>
Jessie Glockner
\n
AdaCore
\n
E: glockner@adacore.com<\/a>
T: +1-646-532-2723\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Innovative software technology enables developing provable, secure communication protocols NEW YORK–(BUSINESS WIRE)–#AdaCore—AdaCore, a trusted provider of software development and verification tools, today announced the launch of its new RecordFlux technology, designed to ease the development and security of binary communication protocols. The technology comprises a Domain Specific Language (DSL) to precisely describe complex binary data … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55256","6":"format-standard","7":"category-industry"},"yoast_head":"\nAdaCore Launches RecordFlux - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AdaCore Launches RecordFlux - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Innovative software technology enables developing provable, secure communication protocols NEW YORK–(BUSINESS WIRE)–#AdaCore—AdaCore, a trusted provider of software development and verification tools, today announced the launch of its new RecordFlux technology, designed to ease the development and security of binary communication protocols. The technology comprises a Domain Specific Language (DSL) to precisely describe complex binary data ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T12:06:47+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adacore-launches-recordflux\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adacore-launches-recordflux\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AdaCore Launches RecordFlux\",\"datePublished\":\"2023-03-28T12:06:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adacore-launches-recordflux\\\/\"},\"wordCount\":551,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adacore-launches-recordflux\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adacore-launches-recordflux\\\/\",\"name\":\"AdaCore Launches RecordFlux - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-28T12:06:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adacore-launches-recordflux\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adacore-launches-recordflux\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adacore-launches-recordflux\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AdaCore Launches RecordFlux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AdaCore Launches RecordFlux - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/","og_locale":"en_US","og_type":"article","og_title":"AdaCore Launches RecordFlux - Pharma Trend","og_description":"Innovative software technology enables developing provable, secure communication protocols NEW YORK–(BUSINESS WIRE)–#AdaCore—AdaCore, a trusted provider of software development and verification tools, today announced the launch of its new RecordFlux technology, designed to ease the development and security of binary communication protocols. The technology comprises a Domain Specific Language (DSL) to precisely describe complex binary data ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-28T12:06:47+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AdaCore Launches RecordFlux","datePublished":"2023-03-28T12:06:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/"},"wordCount":551,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/","url":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/","name":"AdaCore Launches RecordFlux - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-28T12:06:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/adacore-launches-recordflux\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AdaCore Launches RecordFlux"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55256"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55256\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}